发病时年龄对AQP4-IgG神经omyelitis光谱障碍复发和残疾的影响
Pakeeran Siriratnam1,2,3, Vilija G Jokubaitis1,2, Anneke Van Der Walt1,2
1Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Neurology
|March 5, 2026
概括
在aquaporin-4抗体阳性神经omyelitis optica光谱障碍 (AQP4-IgG NMOSD) 中,发病时的年龄较大不会增加复发风险,但会导致更快的残疾. 早期免疫疗法对所有患者至关重要.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床研究 临床研究
背景情况:
- 关于AQP4-IgG NMOSD中发病时的年龄对复发风险的影响存在不一致的发现.
- 在NMOSD中,晚年发病与更快的残疾有关,与多发性硬化症不同,它可能会减少复发活动.
研究的目的:
- 为了澄清在AQP4-IgG NMOSD中开始时的年龄对复发风险和残疾累积的影响.
- 分析一个大型的国际NMOSD患者队列.
主要方法:
- 使用MSBase注册表进行回顾性多中心队列研究.
- 包括539名 AQP4-IgG NMOSD 患者,按发病年龄分层分类:儿科 (<18岁),早期 (18-55岁) 和晚期 (>55岁).
- 评估年度复发率 (ARR),第一次复发的时间,以及使用考克斯比例模型的扩展残疾状况尺度 (EDSS) 4/6的时间.
主要成果:
- 发病时的年龄没有影响ARR或第一次复发的时间.
- 年龄较大与较快的残疾累积有关.
- 高效疗法 (HET) 与低效疗法 (LET) 相比减少了复发;更高的基线EDSS和延迟治疗预测了残疾.
结论:
- 发病时的年龄不会影响AQP4-IgG NMOSD的复发风险.
- 老年患者经历了更快的残疾累积,突出了早期免疫治疗的必要性.
- 追溯设计和依赖EDSS是研究的局限性.
相关概念视频
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
294
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
294
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
771
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
771